Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.01 on Friday. The firm has a 50-day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. The firm has a market cap of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.02.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.